GlassScriptPhysician profile
Heather M Brody
NPI 1013301563
$12,562.04
in general payments reported to CMS, 2019-2025
71 companies · $2,644 in 2025
The $2,644 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,859 · 2020: $480 · 2021: $107 · 2022: $2,106 · 2023: $2,445 · 2024: $2,922 · 2025: $2,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,845 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120 · Education: $44.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,845.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
| Education | $44.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,412.82 | 2019-2025 | |
| Pfizer INC. | $985.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $914.53 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $772.65 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $612.18 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $523.68 | 2022-2025 | Rybrevant, Darzalex, Talvey |
| Seagen INC. | $434.36 | 2020-2023 | Padcev, Tukysa, Adcetris |
| Incyte Corporation | $422.64 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Genentech USA, INC. | $401.34 | 2019-2025 | Tecentriq, Polivy, Columvi |
| Abbvie INC. | $324.91 | 2019-2025 | |
| Astellas Pharma US INC | $295.97 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $275.29 | 2022-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Lilly USA, LLC | $274.33 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Alexion Pharmaceuticals, INC. | $262.01 | 2019-2024 | Ultomiris, Soliris |
| Daiichi Sankyo INC. | $260.75 | 2019-2025 | Enhertu, Datroway |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $252.11 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Celgene Corporation | $245.38 | 2019-2025 | Reblozyl, Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $214.65 | 2019-2023 | Imbruvica, Epkinly |
| Eisai INC. | $206.55 | 2019-2025 | |
| Beone Medicines USA, INC. | $202.11 | 2025 | Brukinsa, Tevimbra |
| Genzyme Corporation | $193.96 | 2019-2025 | |
| Gilead Sciences, INC. | $188.27 | 2022-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $175.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.06 | 2019-2025 | Gilotrif |
| Exelixis INC. | $169.19 | 2019-2025 | Cabometyx |
| Coherus Oncology, INC. | $141.17 | 2021-2024 | |
| Stemline Therapeutics INC. | $136.73 | 2023-2025 | Orserdu, Elzonris |
| Amgen INC. | $133.08 | 2020-2023 | Lumakras, Vectibix, Nplate |
| Tersera Therapeutics LLC | $115.27 | 2020-2024 | Zoladex, Xermelo |
| Jazz Pharmaceuticals INC. | $108.09 | 2019-2024 | |
| Array Biopharma INC | $96.57 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Blueprint Medicines Corporation | $91.10 | 2022-2024 | Ayvakit |
| Beigene USA, INC. | $82.48 | 2022-2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $81.80 | 2023-2025 | Fotivda |
| Karyopharm Therapeutics INC. | $81.47 | 2020-2023 | Xpovio |
| Pharmaessentia USA Corporation | $76.42 | 2022-2025 | Besremi |
| G1 Therapeutics, INC. | $74.25 | 2022 | |
| Tesaro, INC. | $66.95 | 2019 | |
| Rigel Pharmaceuticals, INC. | $64.81 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Kite Pharma, INC. | $64.44 | 2022-2024 | Yescarta |
| Sobi, INC | $58.51 | 2022-2024 | |
| Puma Biotechnology, INC. | $55.06 | 2022-2025 | |
| Kyowa Kirin, INC. | $52.41 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $51.43 | 2020-2025 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $51.29 | 2023-2025 | Qinlock |
| Servier Pharmaceuticals LLC | $47.98 | 2023-2024 | |
| Iovance Biotherapeutics, INC. | $46.49 | 2024-2025 | Amtagvi |
| Shire North American Group INC | $43.68 | 2019 | |
| Adc Therapeutics America, INC. | $42.77 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $41.11 | 2019-2023 | Provenge |
| Sumitomo Pharma America, INC. | $36.10 | 2023-2024 | Orgovyx |
| Adaptive Biotechnologies Corporation | $34.06 | 2024 | Clonoseq |
| Recordati_rare_diseases_inc. | $30.72 | 2025 | Sylvant, Enjaymo |
| Mirati Therapeutics, INC. | $30.69 | 2023 | Krazati |
| Emd Serono, INC. | $29.47 | 2019-2023 | Bavencio |
| Regeneron Healthcare Solutions, INC. | $28.54 | 2023-2025 | Libtayo |
| Cycle Pharmaceuticals INC | $26.09 | 2025 | Phyrago |
| Btg International INC. | $25.46 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $24.71 | 2022 | |
| Secura Bio, INC. | $21.84 | 2019-2020 | |
| Geron Corporation | $21.21 | 2025 | Rytelo |
| Tolmar, INC. | $20.24 | 2025 | Eligard |
| Novocure INC. | $18.32 | 2025 | Optune Lua (Novottf-200t) |
| Global Blood Therapeutics, INC. | $17.16 | 2022 | |
| Acrotech Biopharma INC. | $16.83 | 2024 | Beleodaq |
| Amag Pharmaceuticals, INC. | $15.02 | 2019 | |
| Verity Pharmaceuticals INC. | $14.49 | 2023 | Trelstar |
| Fennec Pharmaceuticals, INC. | $14.38 | 2025 | Fyarro |
| Lexicon Pharmaceuticals, INC. | $14.17 | 2020 | |
| Myovant Sciences INC. | $13.14 | 2022 | |
| Myriad Genetic Laboratories, INC. | $11.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Brody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.